A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer

Yoshiko Akiyama, Yuichiro Ohe, Tomohide Tamura, Masahiro Sawada, Akira Inoue, Hitoshi Kusaba, Noboru Yamamoto, Ikuo Sekine, Hideo Kunitoh, Tetsuro Kodama, Nagahiro Saijo

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: The combination of paclitaxel (225 mg/m2, 3-h infusion) and carboplatin (area under the curve 6) is widely used for non-small cell lung cancer in the USA. In Japan, however, the recommended dose for single-use paclitaxel in 3-h infusion is 210 mg/m2 and the optimal dose of this agent in combination with carboplatin has not been established. This dose escalation study was designed to determine the maximum tolerated dose of paclitaxel in 3-h infusion plus carboplatin at a fixed dose of area under the curve 6 for Japanese patients with advanced, untreated non-small cell lung cancer. Methods: Between October 1999 and May 2000, 19 patients were enrolled and 18 of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin area under the curve 6 and a escalated dose of paclitaxel on day 1 every 3-4 weeks. The initial dose of paclitaxel was 175 mg/m2 and was increased by 25 mg/m2 at each dose level. Results: Neutropenia was the major toxicity observed, but was not dose related. Febrile neutropenia was not observed. No grade 3 or more peripheral neuropathy, myalgia or arthralgia was reported. The maximum tolerated dose was not determined even at the highest paclitaxel dose level (225 mg/m2) in this study. Partial responses were observed in six of the 19 patients (31.6%). Conclusion: We conclude that paclitaxel at 225 mg/m2 in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer.

Original languageEnglish
Pages (from-to)482-487
Number of pages6
JournalJapanese journal of clinical oncology
Volume31
Issue number10
Publication statusPublished - Nov 20 2001
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Area Under Curve
Maximum Tolerated Dose
Febrile Neutropenia
Myalgia
Arthralgia
Peripheral Nervous System Diseases
Neutropenia
Japan
Drug Therapy

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. / Akiyama, Yoshiko; Ohe, Yuichiro; Tamura, Tomohide; Sawada, Masahiro; Inoue, Akira; Kusaba, Hitoshi; Yamamoto, Noboru; Sekine, Ikuo; Kunitoh, Hideo; Kodama, Tetsuro; Saijo, Nagahiro.

In: Japanese journal of clinical oncology, Vol. 31, No. 10, 20.11.2001, p. 482-487.

Research output: Contribution to journalArticle

Akiyama, Y, Ohe, Y, Tamura, T, Sawada, M, Inoue, A, Kusaba, H, Yamamoto, N, Sekine, I, Kunitoh, H, Kodama, T & Saijo, N 2001, 'A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer', Japanese journal of clinical oncology, vol. 31, no. 10, pp. 482-487.
Akiyama, Yoshiko ; Ohe, Yuichiro ; Tamura, Tomohide ; Sawada, Masahiro ; Inoue, Akira ; Kusaba, Hitoshi ; Yamamoto, Noboru ; Sekine, Ikuo ; Kunitoh, Hideo ; Kodama, Tetsuro ; Saijo, Nagahiro. / A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer. In: Japanese journal of clinical oncology. 2001 ; Vol. 31, No. 10. pp. 482-487.
@article{004b9b2176454a5093374557f226a2c9,
title = "A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer",
abstract = "Background: The combination of paclitaxel (225 mg/m2, 3-h infusion) and carboplatin (area under the curve 6) is widely used for non-small cell lung cancer in the USA. In Japan, however, the recommended dose for single-use paclitaxel in 3-h infusion is 210 mg/m2 and the optimal dose of this agent in combination with carboplatin has not been established. This dose escalation study was designed to determine the maximum tolerated dose of paclitaxel in 3-h infusion plus carboplatin at a fixed dose of area under the curve 6 for Japanese patients with advanced, untreated non-small cell lung cancer. Methods: Between October 1999 and May 2000, 19 patients were enrolled and 18 of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin area under the curve 6 and a escalated dose of paclitaxel on day 1 every 3-4 weeks. The initial dose of paclitaxel was 175 mg/m2 and was increased by 25 mg/m2 at each dose level. Results: Neutropenia was the major toxicity observed, but was not dose related. Febrile neutropenia was not observed. No grade 3 or more peripheral neuropathy, myalgia or arthralgia was reported. The maximum tolerated dose was not determined even at the highest paclitaxel dose level (225 mg/m2) in this study. Partial responses were observed in six of the 19 patients (31.6{\%}). Conclusion: We conclude that paclitaxel at 225 mg/m2 in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer.",
author = "Yoshiko Akiyama and Yuichiro Ohe and Tomohide Tamura and Masahiro Sawada and Akira Inoue and Hitoshi Kusaba and Noboru Yamamoto and Ikuo Sekine and Hideo Kunitoh and Tetsuro Kodama and Nagahiro Saijo",
year = "2001",
month = "11",
day = "20",
language = "English",
volume = "31",
pages = "482--487",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - A dose escalation study of paclitaxel and carboplatin in untreated Japanese patients with advanced non-small cell lung cancer

AU - Akiyama, Yoshiko

AU - Ohe, Yuichiro

AU - Tamura, Tomohide

AU - Sawada, Masahiro

AU - Inoue, Akira

AU - Kusaba, Hitoshi

AU - Yamamoto, Noboru

AU - Sekine, Ikuo

AU - Kunitoh, Hideo

AU - Kodama, Tetsuro

AU - Saijo, Nagahiro

PY - 2001/11/20

Y1 - 2001/11/20

N2 - Background: The combination of paclitaxel (225 mg/m2, 3-h infusion) and carboplatin (area under the curve 6) is widely used for non-small cell lung cancer in the USA. In Japan, however, the recommended dose for single-use paclitaxel in 3-h infusion is 210 mg/m2 and the optimal dose of this agent in combination with carboplatin has not been established. This dose escalation study was designed to determine the maximum tolerated dose of paclitaxel in 3-h infusion plus carboplatin at a fixed dose of area under the curve 6 for Japanese patients with advanced, untreated non-small cell lung cancer. Methods: Between October 1999 and May 2000, 19 patients were enrolled and 18 of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin area under the curve 6 and a escalated dose of paclitaxel on day 1 every 3-4 weeks. The initial dose of paclitaxel was 175 mg/m2 and was increased by 25 mg/m2 at each dose level. Results: Neutropenia was the major toxicity observed, but was not dose related. Febrile neutropenia was not observed. No grade 3 or more peripheral neuropathy, myalgia or arthralgia was reported. The maximum tolerated dose was not determined even at the highest paclitaxel dose level (225 mg/m2) in this study. Partial responses were observed in six of the 19 patients (31.6%). Conclusion: We conclude that paclitaxel at 225 mg/m2 in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer.

AB - Background: The combination of paclitaxel (225 mg/m2, 3-h infusion) and carboplatin (area under the curve 6) is widely used for non-small cell lung cancer in the USA. In Japan, however, the recommended dose for single-use paclitaxel in 3-h infusion is 210 mg/m2 and the optimal dose of this agent in combination with carboplatin has not been established. This dose escalation study was designed to determine the maximum tolerated dose of paclitaxel in 3-h infusion plus carboplatin at a fixed dose of area under the curve 6 for Japanese patients with advanced, untreated non-small cell lung cancer. Methods: Between October 1999 and May 2000, 19 patients were enrolled and 18 of these patients were evaluable for toxicity. Chemotherapy consisted of carboplatin area under the curve 6 and a escalated dose of paclitaxel on day 1 every 3-4 weeks. The initial dose of paclitaxel was 175 mg/m2 and was increased by 25 mg/m2 at each dose level. Results: Neutropenia was the major toxicity observed, but was not dose related. Febrile neutropenia was not observed. No grade 3 or more peripheral neuropathy, myalgia or arthralgia was reported. The maximum tolerated dose was not determined even at the highest paclitaxel dose level (225 mg/m2) in this study. Partial responses were observed in six of the 19 patients (31.6%). Conclusion: We conclude that paclitaxel at 225 mg/m2 in 3-h infusion and carboplatin area under the curve 6 can safely be given to Japanese patients with non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=0034753937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034753937&partnerID=8YFLogxK

M3 - Article

C2 - 11696617

AN - SCOPUS:0034753937

VL - 31

SP - 482

EP - 487

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 10

ER -